Latest Insider Transactions at Vir Biotechnology, Inc. (VIR)
This section provides a real-time view of insider transactions for Vir Biotechnology, Inc. (VIR). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Vir Biotechnology, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Vir Biotechnology, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 10
2020
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,340
+8.25%
|
$2,340
$1.53 P/Share
|
|
Nov 04
2020
|
Phillip Pang EVP & Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+12.57%
|
$5,000
$1.53 P/Share
|
|
Nov 02
2020
|
Jay Parrish Chief Business Officer |
SELL
Open market or private sale
|
Direct |
6,944
-3.03%
|
$215,264
$31.27 P/Share
|
|
Nov 02
2020
|
Jay Parrish Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,944
+1.5%
|
$6,944
$1.53 P/Share
|
|
Oct 27
2020
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
3,805
-13.83%
|
$133,175
$35.04 P/Share
|
|
Oct 27
2020
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
3,805
+12.15%
|
$3,805
$1.53 P/Share
|
|
Oct 21
2020
|
Phillip Pang EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
17,500
-15.5%
|
$595,000
$34.15 P/Share
|
|
Oct 21
2020
|
Phillip Pang EVP & Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+9.32%
|
$25,000
$2.76 P/Share
|
|
Oct 13
2020
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
5,560
-19.0%
|
$239,080
$43.03 P/Share
|
|
Oct 13
2020
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,560
+15.97%
|
$5,560
$1.53 P/Share
|
|
Oct 07
2020
|
Phillip Pang EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
12,500
-16.06%
|
$512,500
$41.74 P/Share
|
|
Oct 07
2020
|
Phillip Pang EVP & Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,500
+12.75%
|
$12,500
$1.55 P/Share
|
|
Oct 01
2020
|
Jay Parrish Chief Business Officer |
SELL
Open market or private sale
|
Direct |
6,945
-3.03%
|
$236,130
$34.75 P/Share
|
|
Oct 01
2020
|
Jay Parrish Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,945
+1.5%
|
$6,945
$1.53 P/Share
|
|
Sep 29
2020
|
Herbert Virgin EVP, Research & CSO |
SELL
Open market or private sale
|
Direct |
3,510
-12.9%
|
$133,380
$38.0 P/Share
|
|
Sep 29
2020
|
Herbert Virgin EVP, Research & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
3,510
+11.43%
|
$3,510
$1.53 P/Share
|
|
Oct 16
2019
|
Temasek Holdings (Private) LTD > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
500,000
+8.33%
|
$10,000,000
$20.0 P/Share
|
|
Oct 16
2019
|
Temasek Holdings (Private) LTD > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
4,999,999
+37.5%
|
-
|
|
Oct 16
2019
|
Svf Endurance (Cayman) LTD > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
950,000
+4.03%
|
$19,000,000
$20.0 P/Share
|
|
Oct 16
2019
|
Svf Endurance (Cayman) LTD > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
21,666,666
+50.0%
|
-
|
|
Oct 16
2019
|
Bill & Melinda Gates Foundation |
BUY
Conversion of derivative security
|
Direct |
2,777,777
+50.0%
|
-
|
|
Oct 16
2019
|
Alaska Permanent Fund Corp |
BUY
Open market or private purchase
|
Direct |
1,500,000
+21.26%
|
$30,000,000
$20.0 P/Share
|
|
Oct 16
2019
|
Alaska Permanent Fund Corp |
BUY
Conversion of derivative security
|
Indirect |
4,055,556
+14.24%
|
-
|